

ORIGINAL



Increased incidence of co-infection in critically ill patients with influenza

Ignacio Martin-Loeches^{1,2*} , Marcus J Schultz³, Jean-Louis Vincent⁴, Francisco Alvarez-Lerma⁵, Lieuwe D. Bos³, Jordi Solé-Violán⁶, Antoni Torres⁷ and Alejandro Rodriguez^{8,9}

© 2016 Springer-Verlag Berlin Heidelberg and ESICM

Abstract

Background: Co-infection is frequently seen in critically ill patients with influenza, although the exact rate is unknown. We determined the rate of co-infection, the risk factors and the outcomes associated with co-infection in critically ill patients with influenza over a 7-year period in 148 Spanish intensive care units (ICUs).

Methods: This was a prospective, observational, multicentre study. Influenza was diagnosed using the polymerase chain reaction. Co-infection had to be confirmed using standard bacteriological tests. The primary endpoint of this analysis was the presence of community-acquired co-infection, with secondary endpoints including ICU, 28-day and hospital mortality.

Results: Of 2901 ICU patients diagnosed with influenza, 482 (16.6 %) had a co-infection. The proportion of cases of co-infection increased from 11.4 % (110/968) in 2009 to 23.4 % (80/342) in 2015 ($P < 0.001$). Compared with patients without co-infection, patients with co-infection were older [adjusted odds ratio (aOR) 1.1, 95 % confidence interval 1.1–1.2; $P < 0.001$] and were more frequently immunosuppressed due to existing HIV infection (aOR 2.6 [1.5–4.5]; $P < 0.001$) or preceding medication (aOR 1.4 [1.1–1.9]; $P = 0.03$). Co-infection was an independent risk factor for ICU mortality (aOR 1.4 [1.1–1.8]; $P < 0.02$), 28-day mortality (aOR 1.3 [1.1–1.7]; $P = 0.04$) and hospital mortality (aOR 1.9 [1.5–2.5]; $P < 0.001$).

Conclusions: Co-infection in critically ill patients with influenza has increased in recent years. In this Spanish cohort, age and immunosuppression were risk factors for co-infection, and co-infection was an independent risk factor for ICU, 28-day and hospital mortality.

Keywords: Influenza, Co-infection, Risk factors, Outcome, Intensive care

Introduction

Severe acute respiratory infection with H1N1 influenza emerged in 2009 and was associated with high mortality

*Correspondence: drmartinloeches@gmail.com

¹ Multidisciplinary Intensive Care Research Organization (MICRO), Wellcome Trust-HRB Clinical Research, Department of Clinical Medicine, Trinity Centre for Health Sciences, St James's University Hospital, Dublin, Ireland

Full author information is available at the end of the article

Take-home message: Based on the data presented, co-infection is a very frequent complication in critically ill patients with influenza. *Streptococcus pneumoniae* is still the most frequent pathogen with higher rates of potentially resistant pathogens. Immunosuppression is a risk factor for co-infection.

H1N1 SEMICYUC Working Group investigators are listed in Appendix section.

rates [1]. The use of early antiviral therapy was one of the cornerstones of treatment in severe respiratory infection with influenza, and was associated with better outcomes. Many patients were suspected of having a community-acquired co-infection [2]. Therefore, it was recommended to consider antibacterial treatment on admission, until an accompanying bacterial infection was excluded [3].

Previous studies suggested temporal relationships between influenza and co-infection [4]. Indeed, retrospective analysis of lung biopsies of patients who died from influenza in the pandemic of 1918 suggested bacterial super-infections of the lungs [5]. This was also found for the influenza pandemic in 1957 [6]. *Staphylococcus aureus*, *Streptococcus pneumoniae*, and *Haemophilus influenzae* are the most-cited bacterial causes of co-infection.

However, *Aspergillus* spp. have also been identified as important pathogens [7]. The exact rate of co-infection and its risk factors, however, remained largely unknown. There is also a lack of understanding of the potential impact of co-infection on the outcome of patients with influenza [8].

We hypothesized that community-acquired co-infection is common and independently associated with mortality in intensive care unit (ICU) patients with influenza. Therefore, we reanalysed the data of a prospective observational study on influenza in critically ill patients in Spain from 2009 to 2015, covering four influenza seasons. In addition, we determined risk factors for co-infection.

Patients and methods

Study design

This was a prospective, observational study conducted from 2009 to 2015 in a large cohort of ICUs in Spain. There were four seasons of influenza, based on epidemic threshold rates developed by the Spanish Ministry of Health [9]: one in 2009 during the influenza H1N1 pandemic, one in the winter of 2010 to 2011, one in the winter of 2014, and one in the winter of 2015. During these four seasons (2009, 2010, 2014 and 2015), all patients admitted to the ICU with influenza-like symptoms were systematically tested to confirm respiratory infection with influenza A or bacterial pathogens. Local investigators registered data of consecutive influenza patients in a national registry created by the Spanish Society of Intensive Care Medicine. The institutional review board of Joan XXIII University Hospital approved the original study (IRBref#11,809) and waived the requirement for patients to give individual informed consent due to the observational nature of the study. The participation of 148 ICUs meant that we could monitor and prospectively follow approximately 80 % of the patients admitted to Spanish ICUs with influenza.

Inclusion and exclusion criteria

This reanalysis did not use inclusion or exclusion criteria other than those employed in the original study. However, patients under the age of 16 years and patients admitted from nursing homes or other healthcare facilities were excluded.

Standard care and collection of samples for diagnostic purposes

The Ministry of Health and competent authorities in Spain intensively monitored and audited management of influenza in the national ICUs. Standardized guidelines were used in all centres [10]. Oseltamivir therapy was considered early treatment (ET) if administered within 2 days of the onset of influenza symptoms [2], and empirical antibiotics were started after obtaining a nasopharyngeal swab, endotracheal aspirates and blood. Nasopharyngeal swabs were used for viral testing,

respiratory secretions for quantitative cultures, and blood samples were cultured and used for serological tests. Bronchoalveolar lavage fluids were not obtained because of the high risk of generating aerosols. If present, pleural effusions were punctured for microbiological culture.

Definitions

Co-infection was suspected if a patient had an acute onset of signs and symptoms suggesting lower respiratory tract infection, with radiographic evidence of a pulmonary infiltrate that had no other known cause [11]. Co-infection had to be laboratory confirmed using the Centers for Disease Control and Prevention criteria. If the co-infection was diagnosed within 2 days of hospital admission, it was considered a community-acquired co-infection. The diagnosis was considered definitive if respiratory pathogens were isolated from blood or pleural fluid and if serological tests confirmed a fourfold increase of atypical pathogens, including *Chlamydia* spp., *Coxiella burnetii* and *Moraxella pneumoniae*. Respiratory aspergillosis was considered a 'definite' diagnosis only if *Aspergillus* spp. were identified on histopathology. The diagnosis was considered 'probable' if respiratory pathogens were isolated in endotracheal aspirates. Respiratory aspergillosis was considered a 'probable' diagnosis in the presence of halo or air-crescent signs on computed tomography of the lungs with positive determination of serum galactomannan, and 'possible' if *Aspergillus* spp. were found in endotracheal aspirates [7]. Appropriateness of antibiotic therapy was defined as administration of at least one antimicrobial agent effective against the isolated pathogen.

Study endpoints

The primary endpoint of this analysis was the presence of community-acquired co-infection. Secondary endpoints included ICU, 28-day and hospital mortality, the number of ventilator-free days and patient's survival at day 28. Ventilator-free days were defined as days of successful and complete weaning from mechanical ventilation up to day 28. For subjects who died during this period, the ventilator-free days were counted as 0 [12].

Analysis plan

Firstly, the proportion of cases and rate of co-infection were determined. This rate was calculated per season and comparisons made among seasons. The first season acted as reference season, and calculations were carried out using logistic regression and odds ratios with confidence intervals. This was repeated for each pathogen.

Associations between co-infection and the clinical outcome measures were studied by logistic regression and corrected for potential confounders, which included gender, age, disease severity (APACHE II

score), comorbidities (asthma, chronic obstructive pulmonary disease, chronic heart failure, chronic kidney disease, haematological disease, diabetes mellitus, HIV and immunodeficiency), pregnancy, obesity, oseltamivir treatment, appropriateness of initial antibiotic therapy, acute kidney injury, need for renal replacement therapy, need for invasive mechanical ventilation and presence of septic shock. Potential chronic comorbidities and states that were risk factors for the occurrence of co-infection included asthma, chronic obstructive pulmonary disease, pregnancy, obesity, diabetes mellitus, HIV and immunodeficiency and were also identified by logistic regression. Both analyses started with all potential confounders and backward selection based on *P* value was performed.

Statistical analysis

Discrete variables are expressed as counts with percentage and continuous variables, as means and standard deviation (SD) or as medians with the 25th to 75th interquartile range (IQR). Parametric or nonparametric tests were used for continuous variables as appropriate after the normality of the distribution had been tested. A *P* value <0.05 was considered significant. Differences in patients' demographic and clinical characteristics were assessed using the Chi squared test or Fisher's exact test for categorical variables and Student's *t* test or the Mann–Whitney *U* test for continuous and ordinal variables, where appropriate.

Trends in the rate and proportion of cases of co-infection and causative pathogens were assessed by logistic regression, with 2009 selected as the year of reference. A stepwise backward-selection logistic regression analysis was performed to study the association with outcome. Variable selection was done based on *P* values (<0.10). For all models that had ICU mortality as the dependent variable, the APACHE II score was included as covariate, irrespective of the associated *P* value. Potential explanatory variables were checked for co-linearity prior to inclusion in the regression models using tolerance and variance inflation factor.

All statistical analysis was performed using SPSS v.20.0 for Mac (IBM Corp., Armonk, NY, USA).

Results

Patients

A total of 2901 ICU patients with polymerase chain reaction (PCR)-confirmed influenza were included and analysed (Table 1; Fig. 1); 1581 patients were male (59.1 %) and the mean age was 51.6 ± 15.9 years. All patients were severely ill, with a mean APACHE II score of 16.1 ± 7.6. The mean ICU and hospital length of stay were 13.5 ± 14.6 and 21.4 ± 18.8 days, respectively. ICU mortality, 28-day mortality and hospital mortality were 22.1, 19.7 and 26.2 %, respectively. *S. pneumoniae* was

Table 1 Characteristics of patients included in the study (N = 2901)

Variable	n = 2901
Sex (male) (n, %)	1706, 59.1 %
Age (mean ± SD)	51.6 ± 15.9
APACHE II score (mean ± SD)	16.1 ± 7.6
Asthma (n, %)	291, 10.1 %
Chronic obstructive pulmonary disease (n, %)	608, 21.2 %
Chronic heart failure (n, %)	331, 11.5 %
Chronic kidney disease (n, %)	246, 8.6 %
Haematological diseases (n, %)	197, 6.9 %
Pregnancy (n, %)	109, 3.8 %
Obesity (n, %)	962, 33.5 %
Obesity (BMI > 40) (n, %)	406, 14.1 %
Diabetes mellitus (n, %)	477, 16.6 %
HIV (n, %)	70, 2.4 %
Immunodeficiency (n, %)	311, 10.8 %

the bacterium most often identified, followed by *Pseudomonas aeruginosa* and methicillin-sensitive *S. aureus* (MSSA) (Table 2).

Relative rate of co-infection


Overall, co-infection was diagnosed in 16.6 % of patients. An increasing trend was observed over the years of the study: 11.4 % in 2009, 17.3 % in 2010, 18.8 % in 2014, and as high as 23.4 % in 2015. The odds ratios (OR) for co-infection were 1.6 [1.2–2.2], 1.8 [1.4–2.4] and 2.4 [1.7–3.3] in 2010, 2014 and 2015 respectively (Fig. 2). A significant increase in the rates of *S. pneumoniae*, *P. aeruginosa*, MSSA and *H. influenzae* co-infection over the years was found (Fig. 2). The relative frequency of *Aspergillus* spp. did not increase over the years of the study (Fig. 2).

Risk factors for co-infection

Comorbidities in patients with and without co-infection are shown in Table 3. The likelihood of co-infection increased with age (adjusted OR 1.01 [1.01–1.02]), preceding HIV infection (adjusted OR 2.6 [1.5–4.5]) and immunosuppressive medication (adjusted OR 1.4 [1.02–1.9]). The numbers of days from onset of clinical symptoms to hospital admission, from hospital admission to start of antiviral therapy, and from onset of clinical symptoms to start of antiviral therapy did not differ between patients with and without co-infection (Supplementary Table 1) (Fig. 3).

Clinical outcomes

ICU mortality was not significantly different among influenza types (A-H1N1: 21.9 %; A-H3N2: 24.2 %; B: 18.9 %;



C: 18.8 %; $P = 0.7$) for patients with or without co-infection. Patients with co-infection more often received early oseltamivir treatment than those without co-infection (1428/2419, 59 % vs. 314/482, 65.1 %; $P = 0.01$). However, early oseltamivir treatment was not associated with a significantly lower ICU mortality in patients with (171/259; 66.6 vs. 122/192; 63.5 %; $P = 0.6$) or without co-infection (1187/1982; 59.9 vs. 419/702; 59.7 %; $P = 0.9$). Continuous renal replacement therapy, invasive mechanical ventilation and immunosuppression were independently associated with ICU mortality; the adjusted OR (aOR) values are summarized in Table 4. Co-infection was also independently associated with increased ICU mortality (aOR 1.4, 95 % CI 1.1–1.8; $P < 0.02$; Table 4), 28-day mortality (aOR 1.3, 95 % CI 1.1–1.7; $P = 0.04$) and hospital mortality (aOR 1.9 95 % CI 1.5–2.5; $P < 0.001$). The mean number of ventilator-free days and survival at day 28 were lower in patients with co-infection (12.9, IQR 10.6–14.2 vs. 10.3, IQR 9.6–12.1; $P < 0.001$). A subgroup analysis showed that only positive cultures for *P. aeruginosa* (aOR 2.6, 95 % CI 1.3–5.1; $P = 0.004$) or *Aspergillus*

Table 2 Numbers and proportions of the pathogens isolated in critically ill patients with bacterial co-infection (N = 482)

Pathogen	N	% ⁺	Definitive	Probable	Possible
<i>S. pneumoniae</i>	246	51.04	17	229	0
<i>P. aeruginosa</i>	55	11.4	2	53	0
MSSA	42	8.7	2	40	0
<i>Aspergillus</i> spp.	35	7.2	2*	25**	8
<i>H. influenza</i>	17	3.5	0	17	0
<i>A. baumannii</i>	14	2.9	0	14	0
MRSA	12	2.4	3	9	0
<i>K. pneumoniae</i>	12	2.4	1	11	0
<i>E. coli</i>	11	2.2	1	10	0
<i>L. pneumophila</i>	5	1.1	1	4	0
<i>S. marcescens</i>	4	0.8	1	3	0
<i>S. hominis</i>	4	0.8	4	0	0
<i>E. cloacae</i>	4	0.8	2	2	0
<i>P. jirovecii</i>	4	0.8	0	4	0
<i>M. pneumoniae</i>	4	0.8	1	3	0
<i>C. pneumoniae</i>	3	0.6	1	2	0
<i>M. tuberculosis</i>	3	0.6	0	3	0
<i>S. maltophilia</i>	2	0.4	0	2	0
<i>K. oxytoca</i>	2	0.4	0	2	0
<i>M. morganii</i>	1	0.2	0	1	0
<i>Shewanella</i> spp.	1	0.2	0	1	0
<i>B. fragilis</i>	1	0.2	0	1	0
<i>Nocardia</i> spp.	1	0.2	0	1	0

MRSA methicillin-resistant *Staphylococcus aureus*, MSSA methicillin-sensitive *Staphylococcus aureus*

* Histopathological confirmation

** CT findings compatible with invasive aspergillosis

+ Percentage of all microorganisms

spp. (aOR 4.1, 95 % CI 1.9–9.6; $P = 0.001$) were independent risk factors for ICU mortality when corrected for APACHE II score.

Discussion

We have reported data from the largest prospective study to date evaluating patients with severe influenza admitted to the ICU. The most significant finding was the high rate of co-infection, complicating the clinical course in one out of six critically ill patients with influenza. Moreover, the rate of co-infection steadily increased over the study period and was independently associated with increased mortality.

Previous studies have provided conflicting results regarding the impact of co-infection on patient outcome. For example, a study performed in Europe, identifying *S. pneumoniae* as the most frequent pathogen isolated in co-infection, demonstrated no significant association between co-infection and ICU mortality after adjustment




Fig. 2 Odds ratios for co-infection, stratified by pathogen. Odds ratio and 95 % confidence intervals are shown per epidemic period for all co-infection (upper left) and per pathogen. The dotted line indicates an odds ratio of 1. If the error bars cross this line, the rate is not significantly different from the rate in 2009, the reference year

for confounding factors [13]. In contrast, a retrospective study analysing 683 critically ill patients in the USA with confirmed or probable 2009 influenza A, found that bacterial co-infection, especially with *S. aureus*, was associated with significantly higher mortality [14]. The main differences between these studies were that in the USA study only 62.1 % of the patients had confirmed co-infection and there was a higher rate of *S. aureus*.

All the studies published to date in critically ill patients have focused on only one influenza season, the vast majority of them on the 2009–2010 pandemic season [14–19]. Some studies also attempted to analyse the occurrence and impact of bacterial organisms complicating critical care illness during the previous 12 months [20]. In the current study we present the clinical characteristics and trend of co-infection over the past 7 years

(2009–2015), providing useful information for the management of patients with severe influenza.

Studies analysing the frequency of influenza and bacterial co-infection have reported high heterogeneity. A recent systematic review and meta-analysis of 27 studies analysed the frequency of bacterial co-infection in influenza patients. The results from these studies were highly variable, ranging from 2 to 65 %, although the majority of studies ranged between 11 and 35 % [21]. Our results show a significant increase in occurrence from 11.4 % in 2009 to 23.4 % in 2015. The most frequent pathogen identified in the seven-year period was *S. pneumoniae* followed by *P. aeruginosa* and MSSA. In the last few years the rate of isolation of *S. pneumoniae* has been declining and the rates of *P. aeruginosa* and *H. influenzae* have increased. It is worth mentioning the reappearance of

Table 3 Unadjusted and adjusted risk factors for co-infection in critically ill patients with confirmed influenza infection


Variable	Co-infection			Adjusted OR			
	No N = 2233	Yes N = 451	P value	OR (95 % CI)	P value		
Sex (male) (n, %)	1399	58.1 %	307	63.8 %	0.04		
Age (mean, SD)	51.1	14.9	55.4	16.0	<0.001	1.1 (1.1–1.2)	<0.001
Asthma (n, %)	249	10.4 %	42	8.8 %	0.3		
Chronic obstructive pulmonary disease (n, %)	494	20.6 %	114	23.8 %	0.1		
Chronic heart failure (n, %)	281	11.7 %	50	10.5 %	0.4		
Chronic kidney disease (n, %)	202	8.4 %	44	9.2 %	0.5		
Haematological diseases (n, %)	2234	93.3 %	441	92.3 %	0.4		
Pregnancy (n, %)	102	4.3 %	7	1.5 %	0.02		
Obesity (n, %)	840	35.1 %	122	25.5 %	0.01		
Obesity > 40 BMI (n, %)	358	15.0 %	48	10.0 %	0.04		
Diabetes mellitus (n, %)	401	16.8 %	76	15.9 %	<0.001		
HIV (n, %)	47	2.0 %	23	4.8 %	<0.001	2.6 (1.5–4.5)	0.001
Immunodeficiency (n, %)	243	10.2 %	68	14.2 %	0.01	1.4 (1.1–1.9)	0.03

The multivariate model included age, gender, APACHE II score, asthma, chronic obstructive pulmonary disease, pregnancy, obesity, diabetes mellitus, HIV and immunodeficiency as eligible variables. Backward selection based on *P* value was used to obtain the optimal model

HIV human immunodeficiency virus

methicillin-resistant *S. aureus* (MRSA). When we analysed results for each pathogen individually, we found that co-infection with MSSA, *P. aeruginosa* and *Aspergillus* spp. was associated with significant mortality. These changes in epidemiology over the years may explain why, as shown in our study, co-infection has become an independent risk factor for ICU mortality.

In general, patients presenting with co-infection in our study were older, had more comorbidities (obesity, HIV and immunosuppression) and a higher severity of illness (APACHE and SOFA scores). Whilst HIV and immunosuppression were not identified as independent risk factors for co-infection in previous studies, our data show that these variables were not only associated with an increased rate of co-infection, but were also identified as risk factors for mortality in the post-pandemic period. [1, 22]. In terms of severity, patients with co-infection presented more organ failure (acute kidney injury, need for mechanical ventilation and shock). After adjusting for potentially confounding variables, the presence of co-infection was a risk factor independently associated with mortality. One important finding was the low rate of patients (4 %) with *S. pneumoniae* co-infection and a bacteraemic episode. Whilst the rate has commonly been reported as above 20 % in patients with community-acquired pneumonia, large multicentre studies [23] have also shown low rates (9.2 %). Bacteraemic episodes are associated with a higher fatality rate, and as a result, reports of bacteraemic episodes in patients with influenza have been less closely studied. This warrants further



investigation to determine the virulence by comparing rates of bacteraemic episodes in patients with community-acquired pneumonia with and without influenza.

The delayed administration of antiviral treatment has been reported as a risk factor for ICU mortality [24]. In

Table 4 Unadjusted and adjusted ICU mortality by risk factors of critically ill patients with confirmed influenza infection for ICU mortality

Variable	ICU mortality				P value	Adjusted OR	
	No N = 2091		Yes N = 593			OR (95 % CI)	P value
Sex (male) (n, %)	1200	57.6 %	381	64.2 %	0.04		
Age (mean, SD)	50.5	15.7	55.6	16.1	<0.001		
APACHE II score (mean, SD)	14.6	6.7	21.06	8.4	<0.001	1.1 (1.1–1.2)	<0.001
Asthma (n, %)	234	11.3 %	42	7.1 %	0.003		
Chronic obstructive pulmonary disease (n, %)	442	21.3 %	121	20.6 %	0.7		
Chronic heart failure (n, %)	222	10.7 %	89	15.1 %	0.04		
Chronic kidney disease (n, %)	143	6.9 %	82	13.9 %	<0.001		
Haematological disease (n, %)	93	4.5 %	85	14.5 %	<0.001		
Pregnancy (n, %)	86	4.1 %	13	2.2 %	0.02		
Obesity (n, %)	681	32.8 %	188	32.0 %	0.7		
Diabetes mellitus (n, %)	327	15.8 %	106	18.0 %	0.2		
HIV (n, %)	37	1.8 %	27	4.6 %	<0.001		
Immunodeficiency (n, %)	149	7.2 %	134	22.8 %	<0.001	3.5 (2.6–4.9)	<0.001
Early oseltamivir treatment (n, %)	1254	60 %	352	59.4 %	0.8		
Appropriate antibiotic therapy (n, %)	259	85.2 %	122	83.0 %	0.5		
Corticosteroids (n, %)	408	19.5 %	121	20.4 %	0.6		
Acute kidney injury (n, %)	348	19.0 %	280	49.6 %	<0.001		
Continuous renal replacement therapy (n, %)	93	4.9 %	161	28.4 %	<0.001	4.0 (2.9–5.6)	<0.001
Invasive mechanical ventilation (n, %)	1108	53.0 %	541	91.2 %	<0.001	4.9 (3.5–6.9)	<0.001
Septic shock (n, %)	921	44.0 %	475	80.1 %	<0.001		
Bacterial co-infection (n, %)	304	14.5 %	147	24.8 %	<0.001	1.4 (1.1–1.8)	0.02

Variables that were evaluated for inclusion in the multivariate logistic regression model: age, gender, APACHE II score, asthma, congestive heart failure, chronic kidney disease, haematological patients, pregnancy, HIV, immunodeficiency, appropriate antibiotic, acute kidney injury, continuous renal replacement therapy, invasive mechanical ventilation, septic shock and presence of co-infection

APACHE Acute Physiology and Chronic Health Evaluation, HIV human immunodeficiency virus, OR odds ratio

our study the rate of empirical administration of antiviral agents was high (70 %), and almost all patients received antiviral treatment at the time the PCR became positive (96.6 %). There were no differences in the antiviral treatment given to patients presenting with or without co-infection that could explain why co-infection patients experienced a worse outcome. Interestingly, patients with co-infection experienced a longer delay in the diagnosis of influenza and admission to ICU; however, the number of days from symptom onset to antiviral treatment was not different between those with and without co-infection. These patients may have been diagnosed initially as having community-acquired pneumonia, pending the result of a positive PCR test result for influenza. In spite of this, no difference in the number of days between admission to hospital and antiviral administration was observed between the patients with and without co-infection (5.1 days in both groups). A very surprising finding was the lack of association between appropriate antibiotic use and outcome. Appropriate antibiotic administration has been repeatedly associated with better outcomes

in patients with community-acquired pneumonia [25]. Whilst co-infection was associated with worse outcome, and conversely appropriate antibiotic use did not result in better survival, we speculate that there is an unknown and complex host–pathogen interaction that can explain this finding. Another point is that among all the comorbidities, only severe immunosuppression was associated with worse outcome, supporting the major role of the immune system in the physiopathology of influenza in critically ill patients.

This study describes the clinical characteristics and outcome of the largest series of patients with confirmed RT-PCR influenza to date. The main strength of the study is its prospectively collected, consecutive design that has systematically followed up patients in 148 ICUs throughout Spain. The systematic inclusion of patients in this study and the detailed clinical characteristics recorded have allowed the Spanish healthcare system to determine and monitor patients' characteristics, mortality rates and rate of co-infection. No other European multicentre study with prospective collection of data from critically

ill patients over a period of several years has been published. We recognize that the epidemiology elsewhere may differ; however, it seems likely that in other countries around the globe have a larger population of vulnerable patients (immunosuppressed persons and the elderly) and a higher rate of co-infection than in Spain. Recent studies conducted to identify the epidemiology of pathogens in patients with either community-acquired pneumonia or healthcare-associated pneumonia showed low rates of resistant pathogens in Europe [25]. The changes in the epidemiology of co-infection demonstrated in our study therefore need to be confirmed in other countries, especially in those with higher rates of resistant pathogens.

Several limitations in the design of our study need to be acknowledged. Firstly, in 7.4 % of the patients the outcome was missing. The observational nature of the study does not allow estimation of the cause-and-effect relationship between the risk factors and outcome, as additional confounding factors may not have been identified (risk factors for healthcare-associated pneumonia, timing of antibiotic administration etc.). Of note, four episodes of *Staphylococcus hominis* bacteraemia might be related intravascular catheter-related infections, and diagnosis of aspergillosis was done after ICU admission in all cases but the exact date of a positive result was not captured. Co-infection diagnosis was not standardized and was based mainly on tracheal aspirate obtained immediately after intubation rather than other invasive diagnostic techniques. During the influenza periods, bronchoalveolar lavage was not systematically performed because of the high risk of generating aerosols. Bronchoscopic lavage, protected specimen brushing and transbronchial or transthoracic lung biopsies have potential risks in severely hypoxaemic intubated patients and are uncommon for standard management of patients with severe community-acquired pneumonia [26] [11]. Data on antibiotics timing and patients receiving antibiotics before bacterial sampling were not recorded as per the design of the study.

Secondly, as mentioned above, this study was restricted to Spanish ICUs, so the findings may not be applicable to non-ICU settings or to other countries. Obviously, ICU admission and criteria for endotracheal intubation were not standardized. In addition, the diagnosis of viral infection was based on nasopharyngeal swab where the determination of viral load measurement was not performed. It has been reported that nasal PCR can remain positive for weeks after clinical resolution [27]. However, significant promotion of awareness over the years by regulatory agencies such as the Centers for Disease Control and Prevention and the World Health Organization has helped physicians to treat patients promptly and adequately [28].

Conclusion

In summary, our results reveal that co-infection is diagnosed in one out of every six critically ill patients admitted to the ICU with severe influenza virus infection, with an increasing tendency over recent epidemics. Co-infection in influenza is an independent risk factor associated with higher ICU mortality because almost all patients (with or without co-infection) received antimicrobial therapy. Surprisingly, the use of appropriate antibiotic therapy was not associated with an improved outcome. The virulence of influenza and complex host–pathogen interactions in patients with co-infection deserve further attention in both epidemiological and translational research. This study is the first to show that there is a trend to more co-infection, which is independently associated with worse outcome.

Electronic supplementary material

The online version of this article (doi:10.1007/s00134-016-4578-y) contains supplementary material, which is available to authorized users.

Author details

¹ Multidisciplinary Intensive Care Research Organization (MICRO), Wellcome Trust-HRB Clinical Research, Department of Clinical Medicine, Trinity Centre for Health Sciences, St James's University Hospital, Dublin, Ireland. ² CIBERes, Madrid, Spain. ³ Department of Intensive Care, Academic Medical Center, Amsterdam, The Netherlands. ⁴ Department of Intensive Care, Erasme Hospital, Université libre de Bruxelles, Brussels, Belgium. ⁵ Service of Intensive Care Medicine, Parc de Salut Mar, Universitat Autònoma de Barcelona, Barcelona, Spain. ⁶ Intensive Care Unit, Hospital Universitario Dr. Negrín, CIBERES, Las Palmas de Gran Canaria, Spain. ⁷ Hospital Clínic Barcelona, Universidad Barcelona, CIBERES, Barcelona, Spain. ⁸ Centro de Investigación Biomédica En Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain. ⁹ Critical Care Department, Institut d'Investigació Sanitària Pere Virgili (IISPV), Joan XXIII University Hospital, Universitat Rovira i Virgili, Tarragona, Spain.

Acknowledgments

The authors are grateful to Zieta O'Hagan for language editing.

Compliance with ethical standards

Conflicts of interest

All of the authors declare that no conflict of interest exists.

Role of funding source

The study funder (Spanish Society of Critical Care—SEMICYUC) had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author (IML) had full access to all the data in the study and final responsibility for the decision to submit for publication.

Ethics committee approval

The institutional review board of Joan XXIII University Hospital approved the original study (IRBref#11809).

Appendix No. 1: H1N1 SEMICYUC Working Group investigators

Andalucía : Pedro Cobo (Hospital Punta de Europa, Algeciras); Javier Martins (Hospital Santa Ana Motril, Granada); Cecilia Carbayo (Hospital Torrecardenas, Almería); Emilio Robles-Musso, Antonio Cárdenas, Javier Fierro (Hospital del Poniente, Almería); Ocaña Fernández (Hospital Huerca—Overa, Almería); Rafael Sierra (Hospital Puerta del Mar, Cádiz); M^a Jesús Huertos (Hospital

Puerto Real, Cádiz); Juan Carlos Pozo, R. Guerrero (Hospital Reina Sofía, Córdoba); Enrique Márquez (Hospital Infanta Elena, Huelva); Manuel Rodríguez-Carvajal (Hospital Juan Ramón Jiménez, Huelva); Antonio Jareño, (Hospital del SAS de Jerez, Jerez de la Frontera); José Pomares, José Luis Ballesteros (Hospital Universitario San Cecilio, Granada); Yolanda Fernández, Francisco Lobato, José F. Prieto, José Albofedo-Sánchez (Hospital Costa del Sol, Marbella); Pilar Martínez (Hospital Virgen de la Victoria, Málaga); Miguel Angel Díaz Castellanos, (Hospital Santa Ana de Motril, Granada); Guillermo Sevilla, (Clínica Sagrado Corazón, Sevilla); José Garnacho-Montero, Rafael Hinojosa, Esteban Fernández, (Hospital Virgen del Rocío, Sevilla); Ana Loza, Cristóbal León (Hospital Universitario Nuestra Señora de Valme, Sevilla); Angel Arenzana, (Hospital Virgen de la Macarena, Sevilla), Dolores Ocaña (Hospital de la Inmaculada, Sevilla) Aragón: Manuel Luis Avellanas, Arantxa Lander, S Garrido Ramírez de Arellano, MI Marquina Lacueva (Hospital San Jorge, Huesca); Pilar Luque (Hospital Lozano Blesa, Zaragoza); Ignacio González (Hospital Miquel Servet, Zaragoza); Jose M^a Montón (Hospital Obispo Polanco, Teruel); Jose M^a Díaz, Pilar López-Reina, Sergio Sáez, (Hospital Virgen de la Salud, Teruel). Asturias: Lisardo Iglesias, Carmen Pascual González (Hospital Universitario Central de Asturias—HUCA, Oviedo); Quiroga (Hospital De Cabueñes, Gijón); Águeda García-Rodríguez (Hospital Valle del Nalón, Langreo).

Baleares: Lorenzo Socias, Pedro Ibáñez, Marcío Borges-Sa; A. Socias, Del Castillo A (Hospital Son Llatzer, Palma de Mallorca); Ricard Jordà Marcos (Clínica Rotger, Palma de Mallorca); José M Bonell (USP. Clínica Palmaplanas, Palma de Mallorca); Ignacio Amestarán (Hospital Son Dureta, Palma de Mallorca).

Canarias: Sergio Ruiz- Santana, Juan José Díaz, (Hospital Dr Negrín, Las Palmas de Gran Canaria); Sisón (Hospital Doctor José Molina, Lanzarote); David Hernández, Ana Trujillo, Luis Regalado, (Hospital General la Palma, La Palma); Leonardo Lorente (Hospital Universitario de Canarias, Tenerife); Mar Martín (Hospital de la Candelaria, Tenerife), Sergio Martínez, J.J. Cáceres (Hospital Insular de Gran Canaria).

Cantabria: Borja Suberviola, P. Ugarte, (Hospital Universitario Marqués de Valdecilla, Santander);

Castilla La Mancha: Fernando García-López, (Hospital General, Albacete); Angel Álvaro Alonso, Antonio Pasilla (Hospital General La Mancha Centro, Alcázar de San Juan); M^a Luisa Gómez Grande (Hospital General de Ciudad Real, Ciudad Real); Antonio Albaya, (Hospital Universitario de Guadalajara, Guadalajara); Alfonso Canabal, Luis Marina, (Hospital Virgen de la Salud, Toledo).

Castilla y León: Juan B López Messa, (Complejo Asistencial de Palencia, Palencia), M^a Jesús López Pueyo

(Hospital General Yagüe, Burgos); Zulema Ferreras, (Hospital Universitario de Salamanca, Salamanca); Santiago Macias, (Hospital General de Segovia, Segovia); José Ángel Berezo, Jesús Blanco Varela, (Hospital Universitario Río Hortega, Valladolid), Andaluz Ojeda A (Hospital Universitario, Valladolid); Antonio Álvarez Terrero (Hospital Virgen de la Concha, Zamora), Fabiola Tena Ezpeleta (Hospital Santa Bárbara, Soria)

Cataluña: Rosa M^a Catalán (Hospital General de Vic, Vic); Miquel Ferrer, Antoni Torres (Hospital Clínic, Barcelona); Sandra Barbadillo (Hospital General de Catalunya—CAPIO, Barcelona); Lluís Cabré (Hospital de Barcelona, Barcelona); Assumpta Rovira (Hospital General de l'Hospitalet, L'Hospitalet); Francisco Álvarez-Lerma, Antonia Vázquez, Joan Nolla (Hospital Del Mar, Barcelona); Francisco Fernández, Joaquim Ramón Cervelló (Centro Médico Delfos, Barcelona); Rafael Mañé, J. Ballús, Rosa M^a Granada (Hospital de Bellvitge, Barcelona); Jordi Vallés, Marta Ortíz, C. Guía (Hospital de Sabadell, Sabadell); Fernando Arméstar, Joaquim Páez (Hospital Dos De Mayo, Barcelona); Jordi Almirall, Xavier Balanzo (Hospital de Mataró, Mataró); Elena Arnau, Lluís Llopart, Mercedes Palomar (Hospital Vall d'Hebron, Barcelona); Iñaki Catalán (Hospital Sant Joan de Déu, Manresa); Josep M^a Sirvent, Cristina Ferri, Nerea López de Arbina (Hospital Josep Trueta, Girona); Mariona Badía, Montserrat Valverdú-Vidal, Fernando Barcenilla (Hospital Arnau de Vilanova, Lleida); Mònica Magret, (Hospital Sant Joan de Reus, Reus); MF Esteban, José Luna, (Hospital Verge de la Cinta, Tortosa); Juan M^a Nava, J González de Molina, (Hospital Universitario Mutua de Terrassa, Terrassa); Zoran Josic (Hospital de Igualada, Igualada); Francisco Gurri (Hospital Quirón, Barcelona); Jordi Rello, Alejandro Rodríguez, Thiago Lisboa, Diego de Mendoza, Sandra Treffer (Hospital Universitario Joan XXIII, Tarragona), Rosa María Díaz (Hospital San Camil. Sant Pere de Ribes, Barcelona)

Extremadura: Alberto Fernández-Zapata, Teresa Recio, Abilio Arrascaeta, M^a José García-Ramos, Elena Gallego (Hospital San Pedro de Alcántara, Cáceres); F. Bueno (Hospital Virgen del Puerto, Plasencia).

Galicia: M^a Lourdes Cordero, José A. Pastor, Luis Álvarez—Rocha (CHUAC, A Coruña); Dolores Vila, (Hospital Do Meixoeiro, Vigo); Ana Díaz Lamas (Hospital Arquitecto Marcide, Ferrol); Javier Blanco Pérez, M Ortiz Piquer, (Hospital Xeral—Calde, Lugo); Eleuterio Merayo, Victor Jose López-Ciudad, Juan Cortez, Eva Vilaboy (Complejo Hospitalario de Ourense, Ourense); Eva Maria Saborido, (Hospital Montecelo, Pontevedra); Raul José González, (H. Miguel Domínguez, Pontevedra); Santiago Freita, (Complejo Hospitalario de Pontevedra, Pontevedra).

La Rioja: José Luis Monzón, Félix Goñi (Hospital San Pedro, Logroño).

Madrid: Frutos Del Nogal Sáez, M Blasco Navalpotro (Hospital Severo Ochoa, Madrid); M^a Carmen García-Torrejón, (Hospital Infanta Elena, Madrid); César Pérez-Calvo, Diego López (Fundación Jiménez Díaz, Madrid); Luis Arnaiz, S. Sánchez-Alonso, Carlos Velayos, (Hospital Fuenlabrada, Madrid); Francisco del Río, Miguel Ángel González (Hospital Clínico San Carlos, Madrid); María Cruz Martín, José M^a Molina (Hospital Nuestra Señora de América, Madrid); Juan Carlos Montejo (Hospital Universitario 12 de Octubre, Madrid); Patricia Albert, Ana de Pablo (Hospital del Sureste, Arganda del rey); José Eugenio Guerrero, Jaime Benitez Peyrat (Hospital Gregorio Marañón, Madrid); José A Juliá, Enrique Cerdá, Manuel Alvarez, Carlos Pey, (Hospital Infanta Cristina, Madrid); Montse Rodríguez, Eduardo Palencia (Hospital Infanta Leonor, Madrid); Rafael Caballero, (Hospital de San Rafael, Madrid); Rafael Guerrero (Hospital Reina Sofía, Madrid); Concepción Vaquero, Francisco Mariscal, S. García, (Hospital Infanta Sofía, Madrid); Almudena Simón (Hospital Nuestra Señora del Prado, Madrid); Nieves Carrasco, (Hospital Universitario La Princesa, Madrid); Isidro Prieto, A Liétor, R. Ramos (Hospital Ramón y Cajal, Madrid); Beatriz Galván, Juan C. Figueira, M. Cruz Soriano (Hospital La Paz, Madrid); P Galdós; Bárbara Balandin Moreno (Hospital Puerta de Hierro, Madrid); Fernández del Cabo (Hospital Monte Príncipe, Madrid); Cecilia Hermosa, Federico Gordo (Hospital de Henares, Madrid); Alejandro Algora (Hospital Universitario Fundación Alcorcón, Madrid); Amparo Paredes (Hospital Sur de Alcorcón, Madrid); JA Cambronero (Hospital Universitario Príncipe de Asturias, Madrid); Sonia Gómez-Rosado, (Hospital de Móstoles, Madrid).

Murcia:

Sofía Martínez (Hospital Santa María del Rosell, Murcia); F. Felices Abad, (Hospital Universitario Reina Sofía, Murcia); Mariano Martinez, (Hospital Universitario Virgen de la Arrixaca, Murcia); Sergio Manuel Butí, Gil Rueda, Francisco García (Hospital Morales Messeguer, Murcia).

Navarra: Laura Macaya, Enrique Maraví-Poma, I Jimenez Urra, L Macaya Redin, A Tellería (Hospital Virgen del Camino, Pamplona); Josu Insansti, (Hospital de Navarra, Pamplona).

País Vasco: Nagore González, Pilar Marco, Loreto Vidaur (Hospital de Donostia, San Sebastián); B. Santamaría, (Hospital de Basurto, Bilbao); Juan Carlos Vergara, Jose Ramon Iruetagoiena Amiano, (Hospital de Cruces, Bilbao); Alberto Manzano, (Hospital Santiago Apóstol, Vitoria); Carlos Castillo Arenal (Hospital Txagorritxu, Vitoria).

Valencia: José Blanquer (Hospital Clinic Universitari, Valencia); Roberto Reig Valero, A. Belenger, Susana Altaba (Hospital General de Castellón, Castellón);

Bernabé Álvarez -Sánchez, (Hospital General de Alicante, Alicante); Santiago Alberto Picos, (Hospital Torrevieja Salud, Alicante); Ángel Sánchez-Miralles, (Hospital San Juan, Alicante); Juan Bonastre, M. Palamo, Javier Cebrian, José Cuñat (Hospital La Fe, Valencia); Belén Romero (Hospital de Manises, Valencia); Rafael Zaragoza, (Hospital Dr Peset, Valencia); Virgilio Paricio, (Hospital de Requena, Valencia); Asunción Marques, S. Sánchez-Morcillo, S. Tormo (Hospital de la Ribera, Valencia). J. Latour (H.G Universitario de Elche, Valencia), M Ángel García (Hospital de Sagunto, Castellón).

Received: 25 June 2016 Accepted: 26 September 2016

Published online: 5 October 2016

References

- Napolitano LM, Angus DC, Uyeki TM (2014) Critically ill patients with influenza A(H1N1)pdm09 virus infection in 2014. *JAMA* 311(13):1289–1290. doi:10.1001/jama.2014.2116
- Rodríguez A, Díaz E, Martín-Loeches I et al (2011) Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. *J Antimicrob Chemother* 66:1140–1149. doi:10.1093/jac/dkq511
- Martin-Loeches I, Bermejo-Martin JF, Valles J et al (2013) Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia. *Intensive Care Med* 39:693–702. doi:10.1007/s00134-013-2829-8
- Chertow DS (2012) Contribution of bacterial coinfection to severe influenza infection. *Crit Care Med* 40:1664–1665. doi:10.1097/CCM.0b013e3182451fd8
- Sheng Z-M, Chertow DS, Ambroggio X et al (2011) Autopsy series of 68 cases dying before and during the 1918 influenza pandemic peak. *Proc Natl Acad Sci USA* 108:16416–16421. doi:10.1073/pnas.1111179108
- Giles C, Shuttleworth EM (1957) Postmortem findings in 46 influenza deaths. *Lancet* (London, England) 273:1224–5
- Martin-Loeches I, Valles J (2012) Overtreating or underdiagnosing invasive pulmonary aspergillosis (IPA) in critically ill H1N1 patients: who is right? *Intensive Care Med* 38:1733–1735. doi:10.1007/s00134-012-2677-y
- van der Sluijs KF, van der Poll T, Lutter R et al (2010) Bench-to-bedside review: bacterial pneumonia with influenza—pathogenesis and clinical implications. *Crit Care* 14:219. doi:10.1186/cc8893
- <http://vgripe.isciii.es/gripe/inicio.do>. Accessed 20 June 2016
- Alfageme I, Aspa J, Bello S et al (2005) Guidelines for the diagnosis and management of community-acquired pneumonia. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). *Arch Bronconeumol* 41:272–289
- Mandell LA, Wunderink G, Anzueto A et al (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis* 44(Suppl 2):S27–S72. doi:10.1086/511159
- Schoenfeld DA, Bernard GR, Network ARDS (2002) Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. *Crit Care Med* 30:1772–1777
- Martin-Loeches I, Sanchez-Corral A, Diaz E et al (2011) Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A(H1N1) virus. *Chest* 139:555–562. doi:10.1378/chest.10-1396
- Rice TW, Rubinson L, Uyeki TM et al (2012) Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. *Crit Care Med* 40:1487–1498. doi:10.1097/CCM.0b013e3182416f23
- Kakeya H, Seki M, Izumikawa K et al (2014) Efficacy of combination therapy with oseltamivir phosphate and azithromycin for influenza: a multicenter, open-label, randomized study. *PLoS ONE* 9:e91293. doi:10.1371/journal.pone.0091293

16. Martin-Loeches I, Lisboa T, Rhodes A, et al. (2010) Use of corticosteroid therapy in patients affected by severe pandemic (H1N1) V influenza A infection. *Intensive Care Med*. pp S319–S319
17. Pereira JM, Moreno RP, Matos R et al (2012) Severity assessment tools in ICU patients with 2009 influenza A (H1N1) pneumonia. *Clin Microbiol Infect* 18:1040–1048. doi:[10.1111/j.1469-0691.2011.03736.x](https://doi.org/10.1111/j.1469-0691.2011.03736.x)
18. Parnell GP, McLean AS, Booth DR et al (2012) A distinct influenza infection signature in the blood transcriptome of patients who presented with severe community acquired pneumonia. *Crit Care* 16:R157. doi:[10.1186/cc11477](https://doi.org/10.1186/cc11477)
19. Martin-Loeches I, Papiol E, Rodríguez A et al (2011) Acute kidney injury in critical ill patients affected by influenza A (H1N1) virus infection. *Crit Care* 15:R66. doi:[10.1186/cc10046](https://doi.org/10.1186/cc10046)
20. Muscedere J, Ofner M, Kumar A et al (2013) The occurrence and impact of bacterial organisms complicating critical care illness associated with 2009 influenza A(H1N1) infection. *Chest* 144:39–47. doi:[10.1378/chest.12-1861](https://doi.org/10.1378/chest.12-1861)
21. Klein EY, Monteforte B, Gupta A et al (2016) The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. *Infl Other Respi Viruses* 10:394–403. doi:[10.1111/irv.12398](https://doi.org/10.1111/irv.12398)
22. Martin-Loeches I, Díaz E, Vidaur L et al (2011) Pandemic and post-pandemic influenza A (H1N1) infection in critically ill patients. *Crit Care* 15:R286. doi:[10.1186/cc10573](https://doi.org/10.1186/cc10573)
23. Martin-Loeches I, Lisboa T, Rodriguez A et al (2010) Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. *Intensive Care Med* 36:612–620
24. Muthuri SG, Venkatesan S, Myles PR et al (2014) Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. *Lancet Respir Med* 2:395–404. doi:[10.1016/S2213-2600\(14\)70041-4](https://doi.org/10.1016/S2213-2600(14)70041-4)
25. Vallés J, Martin-Loeches I, Torres A et al (2014) Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study. *Intensive Care Med*. doi:[10.1007/s00134-014-3239-2](https://doi.org/10.1007/s00134-014-3239-2)
26. (2014) NICE. National Institute for Health and Care Excellence. Pneumonia (including community acquired pneumonia). <http://www.nice.org.uk/guidance/cg191>. Accessed 20 June 2016
27. Estella A (2010) Bronchoalveolar lavage for pandemic influenza A (H1N1) v pneumonia in critically ill patients. *Intensive Care Med* 36:1976–1977. doi:[10.1007/s00134-010-2009-z](https://doi.org/10.1007/s00134-010-2009-z)
28. Fowlkes A, Steffens A, Temte J et al (2015) Incidence of medically attended influenza during pandemic and post-pandemic seasons through the Influenza Incidence Surveillance Project, 2009–13. *Lancet Respir Med* 3:709–718. doi:[10.1016/S2213-2600\(15\)00278-7](https://doi.org/10.1016/S2213-2600(15)00278-7)